StemCell InstituteTSE:7096 +0.92%69 PB Ratio is 2.88 as of Jul. 13, 2026, which is 69% below its 10-year median of 9.27. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.29 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,231 Biotechnology companies, StemCell Institute ranks better than 51.1% on this metric.
The historical rank and industry rank for StemCell Institute's PB Ratio or its related term are showing as below:
TSE:7096'
s PB Ratio Range Over the Past 10 Years
Min: 2.45 Med: 9.27 Max: 26.54
Current: 2.88
During the past 9 years, StemCell Institute's highest PB Ratio was 26.54. The lowest was 2.45. And the median was 9.27.
TSE:7096's PB Ratio is ranked better than 51.1% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs TSE:7096: 2.88
During the past 12 months, StemCell Institute's average Book Value Per Share Growth Rate was 3.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.60% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of StemCell Institute was 28.90% per year. The lowest was 5.90% per year. And the median was 19.25% per year.
Back to Basics: PB Ratio
StemCell Institute (TSE:7096) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
StemCell Institute PB Ratio Related Terms
StemCell Institute PB Ratio Historical Data
* Premium members only.
The historical data trend for StemCell Institute's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, StemCell Institute's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's PB Ratio distribution charts can be found below:
* The bar in red indicates where StemCell Institute's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
StemCell Institute (TSE:7096) has a PB Ratio of 2.88 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on StemCell Institute and its competitors. This is 69% below median its historical median of 9.27. Over the past decade, StemCell Institute's PB Ratio has ranged from 2.45 to 26.54. According to the industry distribution chart, StemCell Institute ranks #602 out of 1231 companies in the Biotechnology industry, placing it in the top 48.9%.
Is StemCell Institute's PB Ratio too high?
StemCell Institute's current PB Ratio of 2.88 is 69% below median its 10-year median of 9.27. Over the past 10 years, this metric has ranged from a low of 2.45 to a high of 26.54. The Biotechnology industry median PB Ratio is 2.93. StemCell Institute's value of 2.88 is 1.7% below this industry median. Based on the distribution chart, StemCell Institute ranks #602 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #602 out of 1231 companies for PB Ratio. This puts StemCell Institute in the upper half of its industry. The industry median PB Ratio is 2.93. StemCell Institute's value of 2.88 is 1.7% below this benchmark. Historically, StemCell Institute's own PB Ratio has ranged from 2.45 to 26.54 over the past decade. While the company's 10-year median is 9.27 vs. the industry median of 2.93, StemCell Institute has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCell Institute's current PB Ratio of 2.88 is 1.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current PB Ratio is 2.88, which is 69% below median its own 10-year median of 9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.29, compared to a current price of 円768.00 — trading 57.6% below its estimated fair value. The current PB Ratio is 2.88, which is 69% below median its 10-year median of 9.27 and 1.7% below the Biotechnology industry median of 2.93. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current PB Ratio is 2.88 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.6% below its estimated GF Value™ of 円1,813.29.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
PB Ratio: 2.88 (69% below median its 10-year median of 9.27)
GF Value™: 円1,813.29 vs. price of 円768.00 (57.6% below fair value)
Industry Position: 1.7% below the Biotechnology median (#602 of 1231)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
